DynaPro Plate Reader Optimizes Screening Process for Biotherapeutic Candidates and Formulations
Wyatt Technology Corporation highlights a study recently authored by Martin Skov Neergaard from the Faculty of Health and Medical Sciences at the University of Copenhagen, “Protein-Protein Interactions Investigated by DLS: Determination at High and Low Protein Concentration.” This article outlines the benefits of quantifying protein-protein interactions (PPI) using automated dynamic light scattering (DLS) in high-throughput screening (HTS) mode to identify promising candidates for drug-like properties and establish the suitability of formulations before entering extended stability studies. The study, which used Wyatt Technology’s DynaPro Plate Reader II high-throughput DLS instrument, was published by GIT Laboratory and may be downloaded at www.wyatt.com/AppNotes/DLS.
Therapeutic monoclonal antibodies (mAbs) are effective at treating chronic diseases such as autoimmune disorders and cancer. Long-term stability is an important attribute of any commercial drug molecule, and of great interest in biotherapeutics in particular. Measurements of PPI indicate colloidal stability, correlate closely to stability and viscosity at high protein concentration, and are widely used as stability-indicating parameters (SIPs) in pre-selecting monoclonal antibody biotherapeutic molecules and formulation conditions before launching the arduous process of long-term stability testing. Ordinarily, PPI studies require significant quantities of sample and labor. Optimal screening processes of PPI will allow drug developers to identify and concentrate development on the most promising mAbs and formulations, saving considerable time and money while decreasing time-to-market.
The study showcases some novel uses of DLS to rapidly provide substantial information about the stability and viscosity of a formulation. Traditionally, PPI are quantified by static light scattering (SLS) as the second virial co-efficient (B22), though recently other techniques have come into widespread use. DLS has proven extremely useful in this field as it provides substantially more information regarding SIPs, with less sample, than standard SLS. DLS quantifies PPI via the diffusion interaction parameter (kD), and Neergaard also explored the relative radius method comparing apparent hydrodynamic radii at low and high concentrations. These methods, using kD and relative radius to quantify PPI in a protein solution, make the process of characterization much quicker and simpler than standard methods.
The DynaPro Plate Reader II is capable of running high-throughput, automated HTS-DLS analyses to characterize PPI in standard microwell plates, under multiple conditions in a significantly reduced time frame, making DLS a viable option for SIP screening. As an added benefit, DLS measures the viscosity of highly concentrated proteins with the same high throughput and low sample consumption. The onset points of aggregation or melting may be obtained in the DynaPro via temperature ramps or chemical denaturing, to assess additional SIPs for conformational stability, making the DynaPro DLS plate reader the ultimate tool for developability and formulation screening.
“Techniques for determining protein stability are still widely debated amongst researchers, and a combination of stability-indicating parameters must be weighed to get a complete picture,” explains Dr Daniel Some, Director of Marketing and Principal Scientist at Wyatt Technology, “Optimization of screening processes to reduce time and resources spent on ensuring long-term viability is a key consideration in the drug development process. The DynaPro Plate Reader II ensures comprehensive testing, over a range of conditions in minimal time, and eliminates the need for additional laboratory apparatus when screening the stability-indicating parameters of high concentration protein formulations.”
Related News
-
News WuXi to sell CGT manufacturing unit to US-based Altaris LLC
At the tail end of 2024, Chinese-based CDMO WuXi AppTec announced the signing of their deal with private equity firm Altaris LLC, confirming the sale of WuXi Advanced Therapies, the cell and gene therapy manufacturing arm of WuXi AppTec. -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan Wrap-Up Report: Conference Highlights
Discover the emerging and trending topics of the pharmaceutical industry with our CPHI Milan Conference Highlights, with exclusive insight from pharmaceutical leaders and experts! -
News BIOSECURE Act not included in key defense spending bill for 2025
On December 7, 2024, the Biden administration revealed the 2025 National Defense Authorization Act, an annual defense bill specifying the budget and expenditures of the US Department of Defense. The controversial BIOSECURE Act was notably missing from ... -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Trump 2.0: What does the US election result mean for the healthcare industry?
After Trump won the Presidential election in the US in early November, we take a look at some of the implications a new Trump administration could have on the health and pharmaceutical industry, and on US patients. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance